What is Versantis?
Founded in 2015 and headquartered in Zurich, Switzerland, Versantis AG is a biotech company specializing in liver and pediatric diseases. The company's focus on critical therapeutic areas positions it within a vital segment of the healthcare industry. Its development trajectory suggests a company aiming to address unmet medical needs through innovative solutions.
How much funding has Versantis raised?
Versantis has raised a total of $20.7M across 2 funding rounds:
Series A
$4.5M
Series B
$16.2M
Series A (2017): $4.5M with participation from Healthequity, Zu00fcrcher Kantonalbank, Redalpine Venture Partners, and Occident
Series B (2019): $16.2M led by Finance, Esperante Ventures, investiere, Zurcher Kantonalbank, and Redalpine HealthEquity
Key Investors in Versantis
Esperante Ventures
Esperante Ventures is a private life sciences venture investment group focused on therapeutics and in vitro diagnostics development companies in Europe, North America, and Israel, typically investing between £200,000 and £1m.
investiere
investiere is a leading European startup investment platform for qualified and institutional investors, focusing on European high-tech startups and having invested CHF 30 million in 2018.
Healthequity
HealthEquity, established in 2002, is a provider of solutions for managing healthcare accounts, specializing in health savings and benefits cost management.
What's next for Versantis?
The substantial enterprise-level funding indicates Versantis AG is likely entering a phase of accelerated growth and development. This capital infusion is expected to fuel further research and development initiatives, potentially enabling the company to advance its pipeline candidates through clinical trials and towards commercialization. The strategic nature of the recent investment suggests strong confidence from backers in Versantis's long-term vision and market potential within the specialized fields of liver and pediatric diseases.
See full Versantis company page
